Delayed-Start Analyses in the Phase 3 Solanezumab EXPEDITION3 Study in Mild Alzheimer's Disease.

J Prev Alzheimers Dis · 2018 · PMC12280706 · PMID 29405226

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

nominally significantno p-value reported

In addition, it is important to note that the difference observed between the placebo and solanezumab treatment groups for the ADCS-iADL might be viewed as being only nominally significant since it was not corrected for multiple comparisons.

also in 7,732 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.